khorana risk score
Jump to navigation
Jump to search
Indications
- risk assessment of chemotherapy-associated thrombosis
- predicts risk of venous thromboembolism for cancer patients depending on type of cancer & other factors
- for use in patients with solid tumors & lymphoma
Contraindications
- not for use in patients with brain tumors or multiple myeloma
Procedure
- 5 predictive per-chemotherapy variables:
- site of cancer
- 2 points for very high-risk site: stomach cancer. pancreatic cancer
- 1 point for high-risk site: lung cancer, lymphoma, urogenital cancer
- platelet count >= 350 x 10(9)/L (1 point)
- blood hemoglobin < 10 g/dL &/or use of erythropoiesis-stimulating agents (1 point)
- leukocyte count > 11 x 10(9)/L (1 point)
- body mass index of >=35 kg/m(2) (1 point)
- site of cancer
More general terms
References
- ↑ Khorana AA, Kuderer NM, Culakova E, Lyman GH, Francis CW. Development and validation of a predictive model for chemotherapy-associated thrombosis. Blood 2008 May 15, 111 (10): 4902-7 PMID: https://www.ncbi.nlm.nih.gov/pubmed/18216292 PMCID: PMC2384124 Free PMC article
- ↑ Mulder FI, Candeloro M, Kamphuisen PW et al The Khorana score for prediction of venous thromboembolism in cancer patients: a systematic review and meta-analysis Haematologica. 2019 Jun;104(6):1277-1287. PMID: https://www.ncbi.nlm.nih.gov/pubmed/30606788 PMCID: PMC6545838 Free reference https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6545838/
- ↑ Khorana Risk Score for Venous Thromboembolism in Cancer Patients. https://www.mdcalc.com/khorana-risk-score-venous-thromboembolism-cancer-patients